A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides analyzers for microscopy systems; and DIFF-Line, a hematology lab that handles a smaller amount daily blood samples, as well as consists of three instruments, such as CellaVision DC-1, RAL SmearBox, and RAL StainBox for smearing, staining, and analyzing peripheral blood smears. It also provides CellaVision DC-1 for performing blood cell differentials; and CellaVision DM1200 and CellaVision DM9600 to automate and simplify the process of performing blood and body fluid differentials. In addition, the company’s CellaVision Bone Marrow Aspirate Application enables laboratories to automate, standardize, and simplify morphological examination of bone marrow aspirate samples; CellaVision Peripheral Blood Application enables laboratories to automate, standardize and simplify morphological examination like peripheral blood smears; CellaVision Advanced RBC Application performs a more comprehensive examination for red blood cell morphology; CellaVision Body Fluid Application is for examination body fluid preparations; CellaVision CellAtlas, a library of blood cell images and descriptions created by digital cell morphology experts; CellaVision Review Software removes restrictive constraints from smear review process and performs better; CellaVision Server Software creates a single streamlined workflow within one or multiple testing sites; and CellaVision VET is a veterinary lab. It sells its products to hospitals and commercial laboratories. The company was incorporated in 1994 and is based in Lund, Sweden.
Financial Summary
| Share Statistics | CVLLY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $478.1 | $356.4 | 38% |
|
| Shares Out (Mil) | 2.4 | 41.2 | 9% |
|
| Institutional Ownership | 43.6% | 83.1% | 18% |
|
| Float (Mil) | 19.5 | 36.7 | 28% |
|
| Beta | 0.87 | 0.89 | 51% |
|
| Avg Daily Volume (000s) | 0 | 318 | 0% |
|
| Price Change (52-week) |
na | 55.9% | na |
|
| Growth | CVLLY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 7.5% | 11.8% | 49% |
|
| Net Income (5yr) | 8.8% | (5.8%) | 53% |
|
| EPS (5yr) | 8.8% | 10.6% | 45 |
|
| Dividends (5yr) | 26.7% | 0.0% | 63% |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | CVLLY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $76 | $123 | 24% |
|
| Net Income (TTM) (Mil) | $14 | ($9) | 46% |
|
| EPS (TTM) | $0.579 | ($0.300) | 54% |
|
| Operating Cash Flow (TTM) (Mil) | $21 | ($1) | 41% |
|
| Net Cash Flow (TTM) (Mil) | $6 | $2 | 55% |
|
| Long-Term Debt (Q1) (Mil) | $3 | $21 | 22% |
|
| Enterprise Value (Q1) (Mil) | $469 | $381 | 34% |
|
| Valuation | CVLLY | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.46 | na |
|
| P/E | na | 25.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.3 | na |
|
| Ratios | CVLLY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 68.0% | 59.1% | 80% |
|
| Net Margin | 18.1% | (4.6%) | 76% |
|
| ROA | 11.8% | (9.9%) | 89% |
|
| ROE | 15.0% | (8.5%) | 70% |
|
| Liabilities to Assets | 21.7% | 45.6% | 14% |
|
| F-Score | na | 4 | na |
|
CellaVision AB (publ) did not pass any screens on 11/19/2026.